Spinocerebellar Ataxia Type 3 (SCA3)
Conditions
Interventions
True Stimulation Group:Active transcranial magnetic stimulation treatment
Placebo Stimulation Group:Sham transcranial magnetic stimulation treatment
Sponsors
The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with genetically confirmed SCA3; 2. Aged between 18 and 75 years (inclusive); 3. A total SARA score >= 3, with a "gait" subscore of 2–6; 4. Willing to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with neurological diseases such as epilepsy, intracranial trauma, severe stroke, intracranial infection, and autoimmune encephalitis, or those with potential factors that may induce epilepsy (such as metabolic abnormalities like hyponatremia, hypocalcemia, hypomagnesemia, hypoglycemia, hyperglycemia, renal failure/uremia, liver failure, and thyroid dysfunction). 2. Patients who have undergone brain imaging and were found to have other lesions causing ataxia, or those with secondary cerebellar abnormalities caused by cerebrovascular disease, alcohol, or drugs, or those with movement disorders caused by motor paralysis and musculoskeletal diseases. 3. Patients with severe mental and psychological disorders such as major depressive disorder and schizophrenia. 4. Patients with implanted devices that are susceptible to magnetic fields, such as deep brain stimulators, cardiovascular stents, cardiac pacemakers, artificial heart valves, and cochlear implants. 5. Pregnant women, breastfeeding women, or patients who may be pregnant. 6. Patients with uncontrolled diseases such as arrhythmia, angina pectoris, transient ischemic attack, vascular aneurysm or dissection, systemic infection or fever, and malignant tumors. 7. Patients whose conditions may affect the collection and accuracy of experimental data, such as those with a history of drug or alcohol abuse within the past 12 months, or those currently taking antipsychotic medications or sedative-hypnotic drugs that suppress neural excitability. 8. Patients who have received transcranial magnetic stimulation (TMS) or other physical therapies within the past 3 months. 9. Patients who are currently participating in or have participated in any other clinical trials within the past 6 months. 10. Patients who are unable to cooperate with the treatment and evaluation of the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ataxia score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cognitive;EQ-5D score;BDNF;Near-infrared imaging indicators;Ruidong Quantitative Motor Function;Eye Tracker;Functional magnetic resonance indicators; | — |
Countries
China
Contacts
Public ContactHong Jiang
The Third Xiangya Hospital of Central South University
Outcome results
None listed